Gray L A, Christopherson W M, Hoover R N
Obstet Gynecol. 1977 Apr;49(4):385-9.
A group of 205 women with endometrial carcinoma was matched for age, parity, and year of operation with a group of 205 women who had had hysterectomies for benign disease. In the former group, 32 patients had used conjugated estrogens, while in the latter group 12 had used this hormone, yielding a relative risk of 3.1 (P = 0.0008). Users of other forms of systemic estrogens showed similar elevations in relative risk. Relative risk was related to duration of use, progressing from no evidence of risk among those using the hormone for less than 5 years to an 11.5-fold greater risk for those using it for 10 years or more. Risk was also related to the strength of the medication. The relative risk for users of the 1.25-mg tablets was 12.7 as compared to a two- to fourfold greater risk among users of lesser strength tablets.
一组205例子宫内膜癌女性患者，在年龄、产次和手术年份方面与一组205例因良性疾病接受子宫切除术的女性进行匹配。在前一组中，32例患者使用过结合雌激素，而后一组中有12例使用过这种激素，相对风险为3.1（P = 0.0008）。其他形式全身雌激素的使用者相对风险也有类似升高。相对风险与使用持续时间有关，使用激素少于5年者无风险证据，而使用10年或更长时间者风险高11.5倍。风险还与药物强度有关。1.25毫克片剂使用者的相对风险为12.7，而使用较低强度片剂者的风险高两至四倍。
